Stefanie Krick
Papers
1
Total Citations
38
H-Index
1
About
Dr. Stefanie Krick is a leading pulmonary researcher whose work centers on the molecular mechanisms of airway disease, with a particular focus on mucociliary dysfunction and the role of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in chronic lung conditions. Her major contributions have advanced our understanding of how environmental insults, such as tobacco smoke, disrupt airway homeostasis. In her highly cited 2015 study, "Roflumilast partially reverses smoke-induced mucociliary dysfunction," Dr. Krick demonstrated that the PDE4 inhibitor roflumilast can counteract smoke-induced damage by increasing intracellular cAMP levels, thereby stimulating CFTR function and restoring mucociliary clearance. This work, which has garnered 38 citations, provides a mechanistic rationale for repurposing existing therapies to treat acquired CFTR dysfunction in smokers, a concept with significant translational potential for conditions like COPD. Dr. Krick’s research bridges basic cell biology and clinical application, offering new hope for patients with smoke-related airway diseases. Her findings have been instrumental in highlighting PDE4 inhibition as a viable strategy to mitigate the deleterious effects of smoking on the respiratory epithelium.
Research Focus
Key Achievements
Top Papers
- 1Roflumilast partially reverses smoke-induced mucociliary dysfunction38 citations · 2015